Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Pharmacogenomics and schizophrenia.

Y Kawanishi1, H Tachikawa, T Suzuki

  • 1Department of Psychiatry, Institute of Clinical Medicine, University of Tsukuba, 1-1-1 Tennoudai, Ibaraki 305-8575, Tsukuba, Japan.

European Journal of Pharmacology
|January 3, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Can measurement of CSF α 1-Antichymotrypsin be a useful tool for differential diagnosis of vascular dementia and Alzheimer's disease?

Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association·2015
Same author

Role of 14-3-3 protein and oxidative stress in diabetic cardiomyopathy.

Acta physiologica Hungarica·2009
Same author

CLOCK gene T3111C polymorphism is associated with Japanese schizophrenics: a preliminary study.

European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology·2006
Same author

The Eating Disorder Inventory-2 in Japanese clinical and non-clinical samples: psychometric properties and cross-cultural implications.

Eating and weight disorders : EWD·2004
Same author

A Gip1p-Glc7p phosphatase complex regulates septin organization and spore wall formation.

The Journal of cell biology·2001
Same author

Linked polymorphisms (-333G>T and -286A>G) in the promoter region of the CCK-A receptor gene may be associated with schizophrenia.

Psychiatry research·2001

Pharmacogenomics uses genetic information to tailor antipsychotic drug therapy for schizophrenia, improving treatment effectiveness and safety. This approach analyzes genetic variations to match patients with the most suitable medications, moving towards personalized medicine.

Area of Science:

  • Pharmacogenomics
  • Genetics
  • Psychiatry

Background:

  • Antipsychotic drugs effectively manage schizophrenia symptoms.
  • Significant individual variability exists in patient responses to these drugs.
  • Genetic factors are strongly implicated in these response differences, suggesting personalized pharmacotherapy.

Purpose of the Study:

  • To highlight the importance of pharmacogenomics in developing personalized schizophrenia treatments.
  • To explore how genome-wide analysis can identify genetic determinants of drug response.
  • To advance the prescription of safer and more effective individually tailored drugs.

Main Methods:

  • Utilizing DNA microarray (DNA chip) analysis for genome-wide scanning.
  • Employing high-density single nucleotide polymorphism (SNP) maps.

Related Experiment Videos

  • Focusing on prospective genotyping of schizophrenic patients for relevant genes.

    • Main Results:

    • Pharmacogenomics enables a deeper understanding of genetic influences on disease development and drug response.
    • Genome-wide scanning can identify genetic variations impacting treatment outcomes.
    • The quality of drug response phenotyping is crucial for discovering relevant polymorphisms.

    Conclusions:

    • Pharmacogenomics is key to discovering new schizophrenia treatments.
    • Individualized therapy can be achieved by matching patient genetics with optimal drugs.
    • Prospective genotyping across drug targets, metabolism, and disease pathways will facilitate personalized medicine.